PharmAust has hit a major trial-stage milestone for its monepantel investigational drug – designed to treat amyotrophic lateral sclerosis (ALS). The milestone signifies a crucial progression for ...
Research firm Morgans has slapped a Speculative Buy on PharmAust (ASX:PAA), with a 12 month price target of 42c (versus current price of 18c). Morgans believes that if the company’s drug succeeds, the ...
ASX-listed PharmAust Limited will shortly commence laboratory testing of the effects of its anti-cancer drug, Monepantel on the Coronavirus after entering into an agreement with the Walter and Eliza ...
The milestone signifies a crucial progression for PharmAust (ASX:PAA) in its efforts to gain approval from the US FDA for monepantel (MPL) as a treatment for amyotrophic lateral sclerosis (ALS). By ...
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Research firm Morgans has slapped a Speculative Buy on PharmAust (ASX:PAA), with a 12 month price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results